Golden State Equity Partners Sells 704 Shares of Hologic, Inc. (NASDAQ:HOLX)

Golden State Equity Partners decreased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 19.4% during the fourth quarter, HoldingsChannel reports. The fund owned 2,933 shares of the medical equipment provider’s stock after selling 704 shares during the quarter. Golden State Equity Partners’ holdings in Hologic were worth $211,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Wolff Wiese Magana LLC bought a new stake in shares of Hologic during the 3rd quarter valued at $25,000. General Partner Inc. bought a new stake in shares of Hologic during the fourth quarter valued at about $26,000. First Horizon Advisors Inc. lifted its holdings in shares of Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 134 shares in the last quarter. Cromwell Holdings LLC boosted its position in shares of Hologic by 330.2% in the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 416 shares during the period. Finally, Covestor Ltd grew its stake in Hologic by 23.8% during the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after acquiring an additional 133 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Insiders Place Their Bets

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. This represents a 47.06 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.88% of the stock is owned by company insiders.

Analysts Set New Price Targets

HOLX has been the topic of several recent analyst reports. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. JPMorgan Chase & Co. increased their target price on shares of Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Leerink Partners lowered their target price on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. William Blair reiterated an “outperform” rating on shares of Hologic in a research note on Monday, January 13th. Finally, Needham & Company LLC cut shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price on the stock. in a research note on Monday. Eight investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Hologic currently has a consensus rating of “Moderate Buy” and a consensus target price of $88.92.

Hologic Trading Down 0.2 %

Shares of HOLX opened at $71.58 on Wednesday. Hologic, Inc. has a twelve month low of $68.61 and a twelve month high of $84.67. The company has a market cap of $16.16 billion, a P/E ratio of 21.50, a P/E/G ratio of 2.35 and a beta of 0.98. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The company’s fifty day simple moving average is $73.05 and its 200-day simple moving average is $77.98.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting analysts’ consensus estimates of $1.01. The firm had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.89 earnings per share. As a group, analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.